Clinical Trials Directory

Trials / Sponsors / Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc.

Industry · 9 registered clinical trials — 2 currently recruiting.

StatusTrialPhaseStarted
WithdrawnA Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and
Advanced Solid Tumor, Metastatic Solid Tumor
Phase 12024-11-15
WithdrawnA Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advance
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Phase 12022-07-28
CompletedStudy of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
Advanced Solid Tumor
Phase 12021-12-29
TerminatedA Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRA
KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
Phase 1 / Phase 22021-09-23
TerminatedA Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC
Phase 12021-07-28
RecruitingA Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma
Phase 1 / Phase 22020-03-12
TerminatedStudy of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or M
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation
Phase 1 / Phase 22019-12-06
Active Not RecruitingStudy of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alteration
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Phase 12019-09-05
RecruitingA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rea
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1 / Phase 22017-03-07